<DOC>
	<DOCNO>NCT00255684</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine cyclophosphamide , radiation therapy donor umbilical cord blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well give fludarabine cyclophosphamide together total-body irradiation follow cyclosporine mycophenolate mofetil work treat patient undergo donor umbilical cord blood transplant hematologic cancer .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Total-Body Irradiation Followed Cyclosporine Mycophenolate Mofetil Treating Patients Who Are Undergoing Donor Umbilical Cord Blood Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency , extent , rate donor ( myeloid lymphoid ) engraftment patient serious hematologic malignancy treat nonmyeloablative conditioning regimen comprise fludarabine , cyclophosphamide , low-dose total-body irradiation follow unrelated allogeneic umbilical cord blood transplantation post-transplant immunosuppression comprise cyclosporine mycophenolate mofetil . - Correlate clinical umbilical cord blood-related factor engraftment patient treat regimen . - Determine transplant-related complication , term toxicity , myelosuppression , infection , acute chronic graft-versus-host disease , patient treat regimen . - Determine disease-free overall survival patient treat regimen . - Determine treatment-related mortality patient treat regimen . OUTLINE : This uncontrolled , pilot study . - Nonmyeloablative conditioning regimen : Patients receive fludarabine IV 30 minute daily day -6 -2 cyclophosphamide IV 2 hour day -6 undergo low-dose total-body irradiation ( TBI ) day 0 . - Unrelated allogeneic umbilical cord blood transplantation ( UCBT ) : After completion TBI , patient undergo 1 2 unrelated allogeneic UCBTs day 0 . - Post-transplant immunosuppression : Patients receive oral IV cyclosporine daily begin day -3 continue day 180 oral IV mycophenolate mofetil twice daily day 0-30 . Patients follow periodically 1 year transplantation . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia ( AML ) without history myelodysplastic syndrome , meet 1 follow criterion : In first complete remission ( CR1 ) unfavorable cytogenetics and/or achieve CR1 ≥ 1 course induction therapy Secondary treatmentrelated AML In second complete remission Relapsed ≤ 20 % blast bone marrow AND circulate blast Acute lymphoblastic leukemia ( ALL ) , meet 1 follow criterion : In CR1 unfavorable cytogenetics elevate WBC presentation OR fail achieve CR1 ≥ 4 week induction therapy In second complete remission Relapsed ≤ 20 % blast bone marrow AND circulating blast Other acute leukemic variant allow discretion principal investigator Chronic myelogenous leukemia ( CML ) , meet 1 follow criterion : In first chronic phase AND refractory unable tolerate imatinib mesylate In second chronic phase In first second accelerate phase Myelodysplastic syndrome intermediate 2 highrisk International Prognosis Scoring System ( IPSS ) score , include follow : Refractory anemia Refractory anemia excess blast Chronic myelomonocytic leukemia Myeloproliferative disorder poor prognosis , include follow : Myelofibrosis myeloid metaplasia No ≥ grade 3 myelofibrosis Atypical CML Juvenile myelomonocytic leukemia Other clonal hemopathies accept poor prognosis Multiple myeloma chromosome 13 abnormality and/or progression prior autologous bone marrow transplantation ( BMT ) Chronic lymphocytic leukemia , meet 1 follow criterion : Primary refractory OR relapse refractory disease ( less partial remission ) Relapsed twice prior chemotherapy Lymphoma , meet follow criterion : Hodgkin 's nonHodgkin 's lymphoma &gt; CR1 OR fail primary induction Chemosensitive disease , define &gt; 50 % reduction mass size recent chemotherapy Must meet ≥ 1 follow criterion : Over 45 year age Has undergone prior autologous allogeneic BMT Charlson^ comorbidity score ≥ 2 Must high degree tumor control ( salvage therapy allow ) At high risk treatmentrelated mortality myeloablative conditioning regimen No massive splenomegaly Patients may become eligible splenectomy radiotherapy spleen No 5/6 6/6 HLAmatched relate donor available No wellmatched ( i.e. , ≥ 9/10 HLA match highresolution type ) unrelated donor available PATIENT CHARACTERISTICS : Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) Transaminases ≤ 4 time ULN ( unless due underlie disease ) Renal Creatinine clearance ≥ 50 mL/min Cardiovascular Ejection fraction ≥ 30 % Pulmonary DCLO ≥ 35 % Other Negative pregnancy test No uncontrolled viral , bacterial , fungal infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Radiotherapy See Disease Characteristics Other At least 3 month since prior immunosuppressive therapy At least 10 day since prior salvage therapy patient least morphologic radiologic complete remission</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>